ClinicalTrials.gg
RecruitingNCT07469800Updated May 27, 2026

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

A Phase 3 interventional study of IBI362 and Placebo in Overweight, Obesity and Hypertensive, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Planned enrollment
7th of 22
336 · median 187
Started
2026
with 7 others
Phase 3
6 of 22
3 open now
Primary completion
2026-08
later than 1 of 13 live
Registered
15th of 22
by date
Lead sponsor
12 of 22
Innovent Biologics (Suzhou) Co. Ltd.

Among the 22 studies testing mazdutide in Obesity, this one is the 7th largest by planned enrollment, is one of 8 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 1 of the 13 other live ones, and was the 15th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment

03

Conditions studied

  • Overweight
  • Obesity
  • Hypertensive

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's planned enrollment of 336 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old at the time of signing the form.
  2. Confirmed diagnosis of hypertension.
  3. No prior history of antihypertensive medication treatment at screening; or previously received only one type of antihypertensive medication during the same period and has discontinued all antihypertensive medications for at least 2 weeks prior to screening.
  4. Voluntarily sign the informed consent form and be willing to strictly comply with the requirements and restrictions stated in the informed consent form and the protocol throughout the study, including but not limited to: maintaining a stable diet and exercise routine, receiving the study drug injections as scheduled, and keeping a study diary.

Exclusion criteria

Exclusion Criteria:

  1. The investigator suspects that the participant may be allergic to the components of the study drug or drugs of the same class.
  2. History of orthostatic hypotension, or blood pressure measured at screening meeting the criteria for orthostatic hypotension.
  3. History or diagnostic evidence of secondary hypertension other than obstructive sleep apnea, including but not limited to: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), aortic stenosis, primary aldosteronism, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension.
  4. Concurrent use of beta-blockers within 1 month prior to screening.
  5. Self-reported body weight change > 5 kg within 3 months.
  6. History of acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting, percutaneous coronary intervention (excluding diagnostic angiography), large artery aneurysm or dissecting aneurysm, (TIA), cerebrovascular accident, severe arrhythmia (e.g., ventricular fibrillation, ventricular flutter, atrial fibrillation, atrial flutter, second-degree or higher atrioventricular block, sick sinus syndrome, etc.) within 6 months; or history of decompensated heart failure or heart failure of (NYHA) Class III or IV; or history of severe diseases such as epilepsy or syncope, which the investigator deems unsuitable for trial participation.
  7. Confirmed diagnosis of diabetes mellitus, or laboratory tests showing (HbA1c) ≥ 6.5%, fasting blood glucose ≥ 7 mmol/L and/or random blood glucose ≥ 11.1 mmol/L.
  8. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, acute cholangitis, or symptomatic/treated gallbladder disease (except for participants who have undergone cholecystectomy and are judged eligible by the investigator); or serum amylase or lipase > 2.0 × (ULN); or fasting serum triglycerides ≥ 5.64 mmol/L (500 mg/dl).
  9. Chronic gastrointestinal diseases or systemic diseases that may affect gastrointestinal motility at screening, or use of drugs that may alter gastrointestinal motility, appetite or absorption within 3 months prior to screening.
  10. History or relevant family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    IBI362 treatment Group

    Drug: IBI362

  • Placebo comparator
    Placebo Control Group

    Drug: Placebo

Interventions

  • DrugIBI362

    IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks: * Weeks 1-4: 2 mg QW * Weeks 5-8: 4 mg QW * Weeks 9-24: 6 mg QW * Weeks 25-48: 6/9 mg QW.

  • DrugPlacebo

    Matching placebo will be administered subcutaneously once weekly (QW) for 48 weeks, with the same number of injections as the IBI362 group to maintain study blinding.

07

What researchers measure

Primary outcomes

  1. To evaluate the effect of IBI362 on mean sitting systolic blood pressure (msSBP) compared with placebo at Week 16 of treatment.

    Change from baseline in msSBP at trough (end-of-dosing interval) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. To evaluate the effect of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP) compared with placebo at Week 24 of treatment.

    Change from baseline in Mean Sitting Systolic Arterial Pressure(msSBP) at Week 24.

    Time frame: Week 24

  2. To evaluate the effect of IBI362 on body weight compared with placebo at Weeks 16 and 24 of treatment.

    Percent change from baseline in body weight at Weeks 16 and 24.

    Time frame: Week 16 and Week 24

  3. To evaluate the trough-to-peak ratio of the antihypertensive effect of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP)and Mean Sitting Diastolic Arterial Pressure(msDBP)at Week 16 of treatment.

    Trough-to-peak ratio of the antihypertensive effect on Mean Sitting Systolic Arterial Pressure(msSBP)and Mean Sitting Diastolic Arterial Pressure(msDBP) calculated by ABPM at Week 16.

    Time frame: Week 16

  4. The effects of IBI362 on Mean Sitting Systolic Arterial Pressure(msSBP) compared to placebo were evaluated at each node during treatment.

    At Weeks 4, 8, 12, and 48, changes in msSBP from baseline.

    Time frame: Week 4, 8, 12, and 48

  5. The effects of IBI362 on mean sitting diastolic arterial pressure (msDBP) compared to placebo were evaluated at each node during treatment.

    Changes from baseline in msDBP at Weeks4, 8, 12, 16, 24, and 48.

    Time frame: Week 4, 8, 12, 16, 24, and 48

  6. The effects of IBI362 on mean arterial pressure (MAP) compared to placebo were evaluated at each node during treatment.

    At Weeks 4, 8, 12, 16, 24, and 48, the change of MAP from baseline.

    Time frame: Week 4, 8, 12, 16, 24, and 48

  7. The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.

    At weeks 4, 8, 12, 16, 24, 48, the proportion of participants with an effective rate of msSBP \<140 mmHg and msDBP\<90 mmHg, or a reduction of ≥20 mmHg from baseline in msSBP and/or a decrease in diastolic blood pressure of ≥10 mmHg from baseline in msDBP and not on risk-based salvage therapy.

    Time frame: Week 4, 8, 12, 16, 24, 48

  8. The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.

    At weeks 4, 8, 12, 16, 24, and 48, the rate of blood pressure reduction: the proportion of participants with msSBP\<140 mmHg and msDBP\<90 mmHg without risk-based salvage therapy.

    Time frame: Week 4, 8, 12, 16, 24, and 48

  9. The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.

    Proportion of participants initiating risk-based remedial treatment at each visit.

    Time frame: Week 4, 8, 12, 16, 24, and 48

  10. The effect of IBI362 on blood pressure reduction efficacy and compliance compared to placebo was evaluated at each node during treatment.

    Proportion of participants initiating remedial treatment based on blood pressure compliance at each visit.

    Time frame: Week 4, 8, 12, 16, 24, and 48

  11. The effects of IBI362 on 24-hour of Ambulatory Blood Pressure Monitoring (ABPM) compared with placebo were evaluated at each node during treatment.

    At weeks 8, 12, 16, 24, and 48, the average SBP and mean DBP were changed from baseline during the whole monitoring period monitored by ABPM.

    Time frame: Week 8, 12, 16, 24, and 48

  12. The effects of IBI362 on day-to-night mean SBP and mean DBP of Ambulatory Blood Pressure Monitoring (ABPM) compared with placebo were evaluated at each node during treatment.

    Changes from baseline in daytime and nighttime mean SBP and mean DBP monitored by ABPM at weeks 8, 12, 16, 24, and 48.

    Time frame: Week 8, 12, 16, 24, and 48

  13. During treatment, IBI362 was evaluated for the effects of IBI362 on body weight compared with placebo.

    Percent change in body weight from baseline at week 48.

    Time frame: Week 48

  14. During treatment, IBI362 was evaluated for the effects of IBI362 on body weight compared with placebo.

    At 16, 24, and 48 weeks, changes in weight from baseline.

    Time frame: Week 16, 24, and 48

  15. During treatment, IBI362 was evaluated for the effects of IBI362 on body mass index (BMI) compared with placebo.

    At 16, 24, and 48 weeks, changes in BMI from baseline.

    Time frame: Week 16, 24, and 48

  16. During treatment, IBI362 was evaluated for the effects of IBI362 on waist circumference compared with placebo.

    At 16, 24, and 48 weeks, changes in waist circumference from baseline.

    Time frame: Week 16, 24, and 48

  17. During treatment, IBI362 was evaluated for the effects of IBI362 on fasting blood glucose compared with placebo.

    At 16, 24, and 48 weeks, fasting blood glucose changed from baseline.

    Time frame: Week 16, 24, and 48

  18. During treatment, IBI362 was evaluated for the effects of IBI362 on glycated hemoglobin (HbA1c) compared with placebo.

    At 16, 24, and 48 weeks, HbA1c changed from baseline.

    Time frame: Week 16, 24, and 48

  19. During treatment, IBI362 was evaluated for the effects of IBI362 on total cholesterol (TC).

    Changes from baseline in total cholesterol (TC) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  20. During treatment, IBI362 was evaluated for the effects of IBI362 on low-density lipoprotein cholesterol (LDL-C) compared with placebo.

    Changes from baseline in low-density lipoprotein cholesterol (LDL-C) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  21. During treatment, IBI362 was evaluated for the effects of IBI362 on high-density lipoprotein cholesterol (HDL-C) compared with placebo.

    Changes from baseline in high-density lipoprotein cholesterol (HDL-C) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  22. During treatment, IBI362 was evaluated for the effects of IBI362 on non-high-density lipoprotein (non-HDL-C) compared with placebo.

    Changes from baseline in non-high-density lipoprotein (non-HDL-C) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  23. During treatment, IBI362 was evaluated for the effects of IBI362 on very low-density lipoprotein cholesterol (VLDL-C) compared with placebo.

    Changes from baseline in very low-density lipoprotein cholesterol (VLDL-C) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  24. During treatment, IBI362 was evaluated for the effects of IBI362 on triglycerides (TG) compared with placebo.

    Changes from baseline in triglycerides (TG) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  25. During treatment, IBI362 was evaluated for the effects of IBI362 on Lp(a) compared with placebo.

    Changes from baseline in Lp(a) at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  26. During treatment, IBI362 was evaluated for the effects of IBI362 on Apo B compared with placebo.

    Changes from baseline in Apo B at 16, 24, and 48 weeks.

    Time frame: Week 16, 24, and 48

  27. During treatment, IBI362 was evaluated for the effects of IBI362 on estimated glomerular filtration rate (eGFR) compared with placebo.

    At weeks 16, 24, and 48, the changes in eGFR from baseline.

    Time frame: Week 16, 24, and 48

  28. During treatment, IBI362 was evaluated for the effects of IBI362 on urine protein compared with placebo.

    At weeks 16, 24, and 48, the changes in urine albumin/creatinine ratio from baseline.

    Time frame: Week 16, 24, and 48

  29. During treatment, IBI362 was evaluated for the effects of IBI362 on cystatin-C compared with placebo.

    Week 16, 24, and 48

    Time frame: Change from baseline in cystatin-C at 16, 24, and 48 weeks.

  30. During treatment, IBI362 was evaluated for the effects of IBI362 on blood uric acid compared with placebo.

    At 16, 24, and 48 weeks, the change in blood uric acid from baseline.

    Time frame: Week 16, 24, and 48

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2026, 3 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 3 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 13, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Aug 1, 2026
CompletionEst.
Apr 15, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07469800
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Apr 23, 2026
Primary completion
Aug 1, 2026 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
May 27, 2026

Study contacts

Jie Wei
Contact
jie.wei@innoventbio.com
0512-69566088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion